TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35184905

Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors (PRGF)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (no PRGF)
Number of subjects: 74
Study: 33740977

Group type: COMPARATOR
Intervention: Opioid analgesia alone (standard treatment)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Multimodal analgesia (Pregabalin, Acetaminophen, Naproxen, and opioids if required)
Number of subjects: 62
Study: 35419729

Group type: EXPERIMENTAL
Intervention: Moxibustion at 43 °C combined with acupuncture
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sham acupuncture with moxibustion at 37 °C
Number of subjects: 63
Study: 33834177

Group type: EXPERIMENTAL
Intervention: Isoniazid for two days only (n=17)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Isoniazid for two days followed by moxifloxacin (n=16)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: No isoniazid (n=18)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard therapy (isoniazid for all 14 days, n=18)
Number of subjects: 69
Study: 35576286

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anaesthesia with 12 ml of 0.25% bupivacaine and 1% lignocaine plain (Group T)
Number of subjects: 82

Group type: COMPARATOR
Intervention: General anaesthesia (Group G)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anaesthesia (Group T)
Number of subjects: 82
Study: 35467903

Group type: EXPERIMENTAL
Intervention: Prioritize one behavior
Number of subjects: 1802

Group type: EXPERIMENTAL
Intervention: Prioritize two behaviors
Number of subjects: 1802

Group type: COMPARATOR
Intervention: No prioritization (control)
Number of subjects: 1802
Study: 33940347

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks or 400 mg every 6 weeks by intravenous infusion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC: FOLFOX6/FOLFIRI alone or in combination with bevacizumab/cetuximab)
Number of subjects: 0
Study: 34082792

Group type: EXPERIMENTAL
Intervention: Ayurveda interventions including Agastya Haritaki 6g and Ashwagandha tablet 500mg twice daily orally after meals with warm water and two sessions of yoga (morning 30 minutes and evening 15 minutes) daily for 90 days.
Number of subjects: 110

Group type: COMPARATOR
Intervention: WHO Rehabilitation Self‐Management after COVID‐19 related illness for 90 days.
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Ayurveda interventions
Number of subjects: 110
Study: 32804876

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Oral sucrose
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (no pain intervention)
Number of subjects: 226
Study: 36127739

Group type: EXPERIMENTAL
Intervention: Inhaled aviptadil (67 μg, three times a day for 10 days)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Normal saline (three times a day for 10 days)
Number of subjects: 132
Study: 34023841

Group type: EXPERIMENTAL
Intervention: Dynamic Guided Surgery (DGS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Static Guided Surgery (SGS)
Number of subjects: 22
Study: 36345809

Group type: EXPERIMENTAL
Intervention: Palbociclib and letrozole
Number of subjects: 3836

Group type: COMPARATOR
Intervention: Letrozole only
Number of subjects: 3836
Study: 33965734

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Citalopram and Placebo (combined)
Number of subjects: 0
Study: 32847900

Group type: EXPERIMENTAL
Intervention: Nasal splint and mouth-breathing training (P-group) before surgery
Number of subjects: 200

Group type: COMPARATOR
Intervention: No intervention (C-group)
Number of subjects: 200
Study: 35463514

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 36425919

Group type: EXPERIMENTAL
Intervention: Pre-emptive ultrasound-guided single-shot lateral sciatic nerve block with 20 ml of 0.75% ropivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 30
Study: 32698622

Group type: EXPERIMENTAL
Intervention: Positive nostalgia
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Negative nostalgia
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Coactive nostalgia
Number of subjects: 366
Study: 34560878

Group type: EXPERIMENTAL
Intervention: Distribution of HIV self-test kits
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Receiving HIV self-test kits
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Ever having heard about HIV self-testing
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Willingness to self-test for HIV in front of a sexual partner
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Exposure to peer-led HIV self-testing education and promotion
Number of subjects: 505
Study: 32220099

Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Pain relief
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Pain improvement
Number of subjects: 154
Study: 36130612

Group type: EXPERIMENTAL
Intervention: Renal artery denervation
Number of subjects: 535

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 535

Group type: COMPARATOR
Intervention: Crossover group
Number of subjects: 535

Group type: COMPARATOR
Intervention: Non-crossover group
Number of subjects: 535
Study: 32763109

Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg, paclitaxel 175 mg/m(2), and carboplatin AUC 5; median bevacizumab duration was 6.7 months; 57% received maintenance bevacizumab.
Number of subjects: 150
Study: 36369645

Group type: EXPERIMENTAL
Intervention: MRx1234
Number of subjects: 366

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 366
Study: 33345659

Group type: EXPERIMENTAL
Intervention: Oncokompas (intervention group, n=320)
Number of subjects: 625

Group type: COMPARATOR
Intervention: Control group (6 months waiting list, n=305)
Number of subjects: 625
Study: 32291162

Group type: EXPERIMENTAL
Intervention: Neighborhood Stress Score (NSS) decile
Number of subjects: 0

Group type: COMPARATOR
Intervention: Area Deprivation Index (ADI) decile
Number of subjects: 0
Study: 35468766

Group type: EXPERIMENTAL
Intervention: botulinum toxin‐A plus 3 months of evidence‐based movement training
Number of subjects: 140

Group type: COMPARATOR
Intervention: botulinum toxin‐A plus a handout of exercises
Number of subjects: 140
Study: 32150521

Group type: EXPERIMENTAL
Intervention: Restrictive 72-hour short-term antibiotic strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard antibiotic usage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Restrictive antibiotic strategy
Number of subjects: 0
Study: 35575766

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.5 MAC
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.75 MAC
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sevoflurane at 1 MAC
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol‐remifentanil total intravenous anesthesia alone
Number of subjects: 80
Study: 33453621

Group type: EXPERIMENTAL
Intervention: Nomogram for diagnosing malnutrition
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: Diagnostic tree for malnutrition
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: Classification tree for grading malnutrition
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: Weight loss within 6 months
Number of subjects: 1219
Study: 32379982

Group type: EXPERIMENTAL
Intervention: Wii™ (exergames) group, n=16
Number of subjects: 35

Group type: COMPARATOR
Intervention: Stretching exercises (control group), n=19
Number of subjects: 35
Study: 35587574

Group type: EXPERIMENTAL
Intervention: ArtemiC oral spray, twice daily on Days 1 and 2, beside standard care
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo oral spray, twice daily on Days 1 and 2, beside standard care
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: ArtemiC
Number of subjects: 50
Study: 34536714

Group type: EXPERIMENTAL
Intervention: Cognitive Anxiety Sensitivity Treatment (CAST)
Number of subjects: 105
Study: 33029528

Group type: EXPERIMENTAL
Intervention: PNF stretching technique combined with TENS
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PNF stretching technique alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 34028012

Group type: EXPERIMENTAL
Intervention: Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE), FIO2 1.0, 70 L min−1 during apnoea
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mechanical Ventilation (MV)
Number of subjects: 30
Study: 32503652

Group type: EXPERIMENTAL
Intervention: Dill powder supplementation (3 g/day)
Number of subjects: 42
Study: 33957178

Group type: EXPERIMENTAL
Intervention: Rivaroxaban plus aspirin
Number of subjects: 18278

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 18278
Study: 34049922

Group type: EXPERIMENTAL
Intervention: Exenatide 2 mg weekly
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 33415871

Group type: COMPARATOR
Intervention: Traditional pricking-cupping (TP-C)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Rolling needle pricking-cupping (RNP-C)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Electroacupuncture (EA)
Number of subjects: 96
Study: 32107975

Group type: EXPERIMENTAL
Intervention: Direct Observation of Procedural Skills (DOPS) and Mini‐Clinical Evaluation Exercise (Mini‐CEX)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: DOPS and Mini‐CEX
Number of subjects: 108
Study: 35697440

Group type: EXPERIMENTAL
Intervention: Spinal medial branch nerve block (MBNB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vertebroplasty (VP)
Number of subjects: 0
Study: 33446039

Group type: EXPERIMENTAL
Intervention: 3D‐MOT training (twice per week for 12 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 35949922

Group type: EXPERIMENTAL
Intervention: Adalimumab (40 mg in 0.4 mL), four injections every 3 months
Number of subjects: 140

Group type: COMPARATOR
Intervention: Saline (placebo), four injections every 3 months
Number of subjects: 140
Study: 33436300

Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 23
Study: 35395932

Group type: EXPERIMENTAL
Intervention: App-based intervention designed to support voluntary commitment to abstain from or reduce substance or digital media use over a period of 2 weeks.
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: App-based intervention
Number of subjects: 4500

Group type: COMPARATOR
Intervention: Education-as-usual control arm (waitlist control)
Number of subjects: 4500
Study: 33592011

Group type: COMPARATOR
Intervention: Urban dwelling
Number of subjects: 528

Group type: COMPARATOR
Intervention: Fasting blood glucose level between 203 and 282
Number of subjects: 528

Group type: COMPARATOR
Intervention: Fasting blood glucose level 282 and above
Number of subjects: 528

Group type: COMPARATOR
Intervention: Duration of diabetes mellitus for 10 and more years
Number of subjects: 528

Group type: COMPARATOR
Intervention: Controlling glucose level after developing symptoms
Number of subjects: 528

Group type: COMPARATOR
Intervention: Having high blood pressure
Number of subjects: 528

Group type: COMPARATOR
Intervention: Family history of complication from diabetes mellitus
Number of subjects: 528

Group type: COMPARATOR
Intervention: Exercising 3 times per week for 15 to 30 minutes
Number of subjects: 528

Group type: COMPARATOR
Intervention: Exercising for less than 15 minutes
Number of subjects: 528

Group type: COMPARATOR
Intervention: Waist circumference greater than or equal to 40 inches
Number of subjects: 528
Study: 34995927

Group type: EXPERIMENTAL
Intervention: Nurse-Family Partnership (NFP) program
Number of subjects: 47
Study: 34342086

Group type: EXPERIMENTAL
Intervention: Capecitabine and temozolomide (CAPTEM)
Number of subjects: 130
Study: 35072661

Group type: EXPERIMENTAL
Intervention: gymnastics + NMT (gNMT; n = 16)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: gymnastics only (GYM; n = 15)
Number of subjects: 43

Group type: COMPARATOR
Intervention: maturity-matched control (CON; n = 12)
Number of subjects: 43
Study: 32601665

Group type: EXPERIMENTAL
Intervention: PRESTO‐Play
Number of subjects: 0

Group type: COMPARATOR
Intervention: PRESTO‐Fit
Number of subjects: 0
Study: 33570701

Group type: EXPERIMENTAL
Intervention: Vitamin D3 50,000 IU PO weekly for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 33270145

Group type: EXPERIMENTAL
Intervention: Juul EU (20 mg/ml)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Juul US (59 mg/ml)
Number of subjects: 18

Group type: COMPARATOR
Intervention: OBC
Number of subjects: 18
Study: 32416072

Group type: EXPERIMENTAL
Intervention: Ivosidenib 500 mg once daily
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Ivosidenib
Number of subjects: 185
Study: 34776029

Group type: EXPERIMENTAL
Intervention: Eye masks intervention for three nights after tracheal intubation removal
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine sleep care (Control)
Number of subjects: 40
Study: 33264063

Group type: EXPERIMENTAL
Intervention: COVID-19 risk mitigation plan implemented during Hajj 2020
Number of subjects: 1000
Study: 32725791

Group type: EXPERIMENTAL
Intervention: 3% CO2-enriched gas mixture (8% oxygen + 3% CO2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 5% CO2-enriched gas mixture (8% oxygen + 5% CO2)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pure hypoxic gas (8% oxygen)
Number of subjects: 20
Study: 35377723

Group type: EXPERIMENTAL
Intervention: YEARS rule + D-dimer
Number of subjects: 0

Group type: COMPARATOR
Intervention: D-dimer alone
Number of subjects: 0
Study: 34505019

Group type: EXPERIMENTAL
Intervention: rhTPO plus GCSF
Number of subjects: 30

Group type: COMPARATOR
Intervention: GCSF alone
Number of subjects: 30
Study: 34050857

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy for Suicide Prevention + treatment as usual (CTSP + TAU) (N=75)
Number of subjects: 150

Group type: COMPARATOR
Intervention: treatment as usual (TAU) alone (N=75)
Number of subjects: 150
Study: 34968972

Group type: EXPERIMENTAL
Intervention: Multiphase Optimization Strategy (MOST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Factorial experiment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sequential Multiple-Assignment Randomized Trial (SMART)
Number of subjects: 0
Study: 32493066

Group type: EXPERIMENTAL
Intervention: Concussion Coach cell phone application
Number of subjects: 35
Study: 34259369

Group type: EXPERIMENTAL
Intervention: Cold lateral compaction
Number of subjects: 45

Group type: COMPARATOR
Intervention: Continuous-wave obturation
Number of subjects: 45

Group type: COMPARATOR
Intervention: New generation thermoplastic core carrier
Number of subjects: 45
Study: 33986878

Group type: EXPERIMENTAL
Intervention: Booklet
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Booklet + Oral Presentation
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Booklet + Oral Presentation + Clinical Teaching
Number of subjects: 160

Group type: COMPARATOR
Intervention: Routine Education
Number of subjects: 160
Study: 32430272

Group type: EXPERIMENTAL
Intervention: Standard suction
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Slow-pull suction
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Wet suction
Number of subjects: 300
Study: 34351822

Group type: EXPERIMENTAL
Intervention: Virtual visits for cancer care
Number of subjects: 21362

Group type: COMPARATOR
Intervention: In-person visits for cancer care
Number of subjects: 21362

Group type: EXPERIMENTAL
Intervention: Virtual visits
Number of subjects: 21362
Study: 33021606

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (15 mg twice daily for 2 weeks, followed by clarithromycin [500 mg daily] for 12 weeks)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo for 14 weeks
Number of subjects: 126

Group type: COMPARATOR
Intervention: Oral prednisolone (15 mg twice daily for 2 weeks, followed by placebo for 12 weeks)
Number of subjects: 126
Study: 32730905

Group type: EXPERIMENTAL
Intervention: Apixaban (2.5 mg twice daily) plus aspirin (100 mg once daily) for 12 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Clopidogrel (75 mg daily) for at least 3 months on a background of aspirin (100 mg once daily) for 12 months
Number of subjects: 200
Study: 34212177

Group type: EXPERIMENTAL
Intervention: Provider-targeted intervention including education on appropriate RTD prescribing and monthly peer comparison feedback.
Number of subjects: 185755

Group type: EXPERIMENTAL
Intervention: Provider-targeted intervention for tier 2 RTDs.
Number of subjects: 185755

Group type: EXPERIMENTAL
Intervention: Provider-targeted intervention for tier 3 RTDs.
Number of subjects: 185755

Group type: EXPERIMENTAL
Intervention: Provider-targeted intervention for tier 1 RTDs.
Number of subjects: 185755
Study: 34000295

Group type: EXPERIMENTAL
Intervention: Immersive seminar
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional lecture
Number of subjects: 26
Study: 32541462

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch (BTP) 10 mg for 14 days
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional analgesic regimen (IV paracetamol 1 mg every 8 hours alternating with parenteral tramadol 50 mg every 8 hours for the first 2 postoperative days, followed by oral administration of the same drug until the end of 2 weeks)
Number of subjects: 160
Study: 35305278

Group type: EXPERIMENTAL
Intervention: HEAT (5 × 50 min weekly heat suit training sessions)
Number of subjects: 25

Group type: COMPARATOR
Intervention: CON (matched for training volume and intensity distribution)
Number of subjects: 25
Study: 32781256

Group type: EXPERIMENTAL
Intervention: iliac bone graft along with injectable and advanced platelet rich fibrin
Number of subjects: 30

Group type: COMPARATOR
Intervention: iliac bone graft alone
Number of subjects: 30
Study: 33861738

Group type: EXPERIMENTAL
Intervention: SNPs analysis for IL37 rs2723186
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: SNPs analysis for IL10 rs1800872
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: SNPs analysis for IL10 rs3024496
Number of subjects: 116
Study: 34627636

Group type: EXPERIMENTAL
Intervention: Job advertisement posters emphasizing future career prospects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard recruitment process without career emphasis
Number of subjects: 0
Study: 32289791

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0
Study: 35238765

Group type: EXPERIMENTAL
Intervention: MIV-711 100 mg
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: MIV-711 200 mg
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 32434362

Group type: EXPERIMENTAL
Intervention: Plum blossom needle acupuncture with qi-invigorating superficies-consolidating therapy
Number of subjects: 87

Group type: COMPARATOR
Intervention: Conventional Western medicine
Number of subjects: 87
Study: 36185308

Group type: EXPERIMENTAL
Intervention: Minimally invasive radical antegrade modular pancreatosplenectomy (MI-RAMPS)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Open radical antegrade modular pancreatosplenectomy (open RAMPS)
Number of subjects: 250
Study: 33992812

Group type: EXPERIMENTAL
Intervention: NaOCl/EDTA with PDT (Curcumin‐PS‐CP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: NaOCl/EDTA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sealapex (Gp 3 and Gp 4)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MTA Fillapex (Gp 5 and Gp 6)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: MTA Fillapex with PDT (Gp 6)
Number of subjects: 60
Study: 35477413

Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy for Children (KIDNET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 34392492

Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide (Gr.A)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Erythromycin (Gr.B)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo (Gr.C)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Metoclopramide (Gr.A)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Resolution of FI within 72-h
Number of subjects: 83
Study: 33558193

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33602325

Group type: EXPERIMENTAL
Intervention: Moderate intensity treadmill exercise (20 min, 70–75% of their maximal heart rate)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Seated rest (20 min)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test for Children (14 min)
Number of subjects: 103
Study: 32318103

Group type: EXPERIMENTAL
Intervention: Real TBS and real RHI
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham TBS and real RHI
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham TBS and sham RHI
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Real TBS and sham RHI
Number of subjects: 22
Study: 33481251

Group type: EXPERIMENTAL
Intervention: Acute intravenous glucose-induced hyperglycaemia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Octreotide-maintained euglycaemia
Number of subjects: 0
Study: 32509972

Group type: EXPERIMENTAL
Intervention: STAR (augmented reality telementoring platform)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Remote audio-only guidance
Number of subjects: 0
Study: 616649626

Group type: EXPERIMENTAL
Intervention: Anticipatory processing prior to a threat of a speech task
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control condition with no social evaluative threat
Number of subjects: 100
Study: 36126236

Group type: EXPERIMENTAL
Intervention: Exercise group (4-month training, 60 min/session, 3 d/wk)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Counseling group (attended conferences on healthy lifestyle)
Number of subjects: 150
Study: 33495489

Group type: EXPERIMENTAL
Intervention: 4 hours of head-down bed rest (HDBR)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (pre-HDBR)
Number of subjects: 14
Study: 33036887

Group type: EXPERIMENTAL
Intervention: CLADS-driven propofol TIVA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual controlled propofol TIVA
Number of subjects: 0